Uterine and Adnexa Procedures for Ovarian or Adnexy DRG

Perioperative multimodal intervention trials evaluating approaches to reduce surgical morbidity and length of stay in patients undergoing hysterectomy or staging procedures for ovarian or adnexal malignancy with major complications or comorbidities. These studies enroll inpatient women classified under this DRG who require complex abdominal or pelvic surgery and have significant physiologic instability (eg, sepsis, hemorrhage, organ dysfunction) to test bundles such as optimized fluid management, enhanced recovery after surgery (ERAS) adaptations for high-risk cases, and targeted ICU pathways. Results inform providers and payers about strategies that can safely shorten intensive resource use, reduce complication-related readmissions, and potentially lower overall inpatient costs for this high-acuity population.
Comparative effectiveness studies of surgical extent and timing in advanced ovarian/adnexal cancer presenting with complications, comparing immediate primary cytoreductive surgery versus staged or neoadjuvant approaches in patients with major complications or frailty. These trials focus on patients who meet this DRG because their malignancy is complicated by acute physiologic compromise or comorbidities, examining outcomes such as in-hospital mortality, complication rates, time to chemotherapy, and resource utilization. Findings guide clinicians and payers on which care pathways balance oncologic benefit with acceptable inpatient risk and costs for patients who are not straightforward candidates for standard primary surgery.
Post-discharge outcomes and care coordination research tracking readmissions, functional recovery, and downstream costs among survivors of complicated uterine/adnexal oncologic surgery, often including frail or elderly patients with major complications. These observational cohorts or pragmatic trials test discharge planning interventions, home-based monitoring, and tailored rehabilitation to reduce 30- and 90-day readmissions and late complications. Insights are directly relevant to hospitals and payers seeking to improve transitions of care, reduce avoidable readmission penalties, and allocate post-acute resources effectively for this high-risk DRG cohort.

Perioperative multimodal intervention trials evaluating approaches to reduce surgical morbidity and length of stay in patients undergoing hysterectomy or staging procedures for ovarian or adnexal malignancy with major complications or comorbidities. These studies enroll inpatient women classified under this DRG who require complex abdominal or pelvic surgery and have significant physiologic instability (eg, sepsis, hemorrhage, organ dysfunction) to test bundles such as optimized fluid management, enhanced recovery after surgery (ERAS) adaptations for high-risk cases, and targeted ICU pathways. Results inform providers and payers about strategies that can safely shorten intensive resource use, reduce complication-related readmissions, and potentially lower overall inpatient costs for this high-acuity population.
Comparative effectiveness studies of surgical extent and timing in advanced ovarian/adnexal cancer presenting with complications, comparing immediate primary cytoreductive surgery versus staged or neoadjuvant approaches in patients with major complications or frailty. These trials focus on patients who meet this DRG because their malignancy is complicated by acute physiologic compromise or comorbidities, examining outcomes such as in-hospital mortality, complication rates, time to chemotherapy, and resource utilization. Findings guide clinicians and payers on which care pathways balance oncologic benefit with acceptable inpatient risk and costs for patients who are not straightforward candidates for standard primary surgery.
Post-discharge outcomes and care coordination research tracking readmissions, functional recovery, and downstream costs among survivors of complicated uterine/adnexal oncologic surgery, often including frail or elderly patients with major complications. These observational cohorts or pragmatic trials test discharge planning interventions, home-based monitoring, and tailored rehabilitation to reduce 30- and 90-day readmissions and late complications. Insights are directly relevant to hospitals and payers seeking to improve transitions of care, reduce avoidable readmission penalties, and allocate post-acute resources effectively for this high-risk DRG cohort.

OpenPayer

Summary & Overview

Uterine and Adnexa Procedures for Ovarian or Adnexal Malignancy with MCC: Inpatient Reimbursement Overview

DRG 736 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes